Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 4/20 | 0.39 |
| ▸ | F13A1 | P00488 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193042 | 0.84 | ALDH1A1 (0.51) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL2193039 | 0.84 | ALDH1A1 (0.51) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL23823914 | 0.77 | HCAR2 (0.48) | SMN1; SMN2ALDH1A1KEAP1NFE2L2HCAR2 | |
| SCHEMBL30418583 | 0.77 | USP2 (0.43) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL16090965 | 0.76 | ALDH1A1 (0.40) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL334091 | 0.76 | USP2 (0.60) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL698803 | 0.76 | USP2 (0.69) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL18294 | 0.76 | USP2 (0.69) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL743795 | 0.75 | EPHX1 (0.49) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 | |
| SCHEMBL743796 | 0.75 | EPHX1 (0.49) | USP2SMN1; SMN2EPHX2ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139593-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-04 | — | — | US | disclosed |
| WO-2021179049-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | THE UNIVERSITY OF ADELAIDE (AU) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139593-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME | GPX4, TXNRD2, TXN2 | USP2 3684/4885SMN1; SMN2 173/4885EPHX2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.